# Trajectory analysis reveals an uncommitted neuroblastic state in MYCN-driven neuroblastoma development

## TL;DR

This study identifies a new cell type in neuroblastoma that may explain why some tumors regress on their own, offering insights for better treatments.

## Contribution

The discovery of an uncommitted neuroblastic cell subtype linked to spontaneous regression in neuroblastoma.

## Key findings

- Uncommitted cells show neuronal gene expression and are more common in cases of failed tumorigenesis.
- Higher uncommitted gene expression in clinical samples correlates with better patient outcomes.
- The findings provide a new molecular signature for understanding tumor regression in neuroblastoma.

## Abstract

Understanding the factors that determine the spontaneous regression of pre-cancerous lesions is critical to advancing cancer prevention. Neuroblastoma, a pediatric cancer, undergoes spontaneous regression more frequently than other types of cancer.

Here, we analyzed the transcriptomic features of spontaneous regression in pre-cancerous neuroblasts using Th-MYCN mice, an animal model that closely resembles human neuroblastoma. Single-cell transcriptomic analysis of ganglion tissues from Th-MYCN mice was conducted to elucidate the cellular and molecular underpinnings.

Trajectory analysis of pre-cancerous neuroblasts revealed a distinct subtype we designated as “uncommitted” cells, characterized by the expression of neuronal genes, indicative of a semi-differentiated state. Samples with predicted failed tumorigenesis had a greater proportion of these uncommitted cells, hinting at their association with spontaneous regression. In clinical specimens, heightened uncommitted gene expression corresponded with favorable neuroblastomas and an improved prognosis.

Collectively, the identification of this novel neuroblastoma-related cell subtype and its transcriptomic signature not only enhances our understanding of spontaneous regression mechanisms but also holds potential for therapeutic advancements in treating neuroblastomas.

Graphical Abstract